Omeros’ OMS906 Data Presented at Complement-based Drug Development Summit
October 16 2020 - 7:30AM
Business Wire
Omeros Corporation (Nasdaq: OMER) presented data from its OMS906
program yesterday at the 4th Complement-based Drug Development
Summit. OMS906 is the company’s lead human monoclonal antibody
targeting mannan-binding lectin-associated serine protease-3
(MASP-3), the key activator of the complement system’s alternative
pathway. The presentation about the inhibition of the alternative
pathway by targeting MASP-3 was made by Jason Cummings, Ph.D.,
Omeros’ Associate Director for Research. Dr. Cummings’ slide
presentation can be viewed at
https://investor.omeros.com/presentations.
Believed to be the premier target in the alternative pathway,
MASP-3 is responsible for the conversion of pro-complement factor D
to mature complement factor D (CFD), and OMS906 is designed to
block that conversion. The presentation included data demonstrating
that a single dose of OMS906 in an animal study demonstrated a
decrease of mature CFD and an increase and accumulation in pro-CFD
levels that remained detectable for more than three weeks. Data
also showed that lowest levels of detectable mature CFD correlated
with complete inactivation of the alternative pathway.
Omeros expects OMS906 to have broad application in conditions
involving inflammation and tissue damage as well as disorders
associated with dysregulation of the alternative pathway.
Paroxysmal nocturnal hemoglobinuria (PNH) is targeted as the
initial indication, and OMS906 has shown greater potency compared
to C5 and C3 inhibitors in PNH models. OMS906, by leaving intact
the adaptive immune effector function of complement, is also
expected to have a more favorable safety profile than C5 and C3
inhibitors.
The targeted OMS906 long-term dosing regimen is once monthly
subcutaneous administration. A Phase 1, placebo-controlled,
double-blind, single-ascending-dose and multiple-ascending-dose
study of OMS906 began dosing subjects last month.
About OMS906
OMS906 is an investigational human monoclonal antibody targeting
mannan-binding lectin-associated serine protease-3 (MASP-3), the
key activator of the complement system’s alternative pathway. The
complement system plays a central role in inflammation and becomes
activated as a result of tissue damage or microbial infection.
Responsible for the conversion of pro-complement factor D to
complement factor D, MASP-3 is believed to be the premier target in
the alternative pathway – it has the lowest native circulating
level and low relative clearance compared to the other alternative
pathway proteins and, unlike C5 and C3 blockers, MASP-3 inhibition
leaves intact the lytic arm of the classical pathway, important for
fighting infection. MASP-3 inhibitors are thought to have
preventive or therapeutic effects across a broad range of diseases
including paroxysmal nocturnal hemoglobinuria (PNH), hemolytic
uremic syndrome (HUS), atypical HUS, traumatic brain injury,
arthritis, wet age-related macular degeneration,
ischemia-reperfusion injury, transplant-related complications and
other immune-related disorders. Through its growing intellectual
property position, Omeros controls the use of MASP-3 inhibitors
across a wide range of alternative pathway-related and other
diseases and disorders.
About Omeros Corporation
Omeros is a commercial-stage biopharmaceutical company committed
to discovering, developing and commercializing small-molecule and
protein therapeutics for large-market and orphan indications
targeting inflammation, complement-mediated diseases, disorders of
the central nervous system and immune-related diseases, including
cancers. In addition to its commercial product OMIDRIA
(phenylephrine and ketorolac intraocular solution) 1%/0.3%, Omeros
has multiple late-stage clinical development programs focused on
complement-mediated disorders, including COVID-19, and substance
abuse. A rolling biologics license application for narsoplimab, the
company’s lead MASP-2 inhibitor, in hematopoietic stem cell
transplant-associated thrombotic microangiopathy is being completed
for submission to the U.S. FDA. Omeros also has a diverse group of
preclinical programs including GPR174, a novel target in
immuno-oncology that modulates a new cancer immunity axis recently
discovered by Omeros. Small-molecule inhibitors of GPR174 are part
of Omeros’ proprietary G protein-coupled receptor (GPCR) platform
through which it controls 54 new GPCR drug targets and their
corresponding compounds. The company also exclusively possesses a
novel antibody-generating platform.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, which are
subject to the “safe harbor” created by those sections for such
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “anticipate,” “believe,” “can,” “could,” “estimate,”
“expect,” “goal,” “intend,” “likely”, “look forward to,” “may,” “on
track,” “plan,” “potential,” “predict,” “project,” “prospects,”
“scheduled,” “should,” “slated,” “targeting,” “will,” “would” and
similar expressions and variations thereof. Forward-looking
statements, including statements regarding anticipated regulatory
submissions, the timing and results of ongoing or anticipated
clinical trials, and the therapeutic application of Omeros’
investigational product, are based on management’s beliefs and
assumptions and on information available to management only as of
the date of this press release. Omeros’ actual results could differ
materially from those anticipated in these forward-looking
statements for many reasons, including, without limitation,
availability and timing of data from clinical trials and the
results of such trials, unproven preclinical and clinical
development activities, regulatory oversight, intellectual property
claims, competitive developments, litigation, and the risks,
uncertainties and other factors described under the heading “Risk
Factors” in the company’s Annual Report on Form 10-K for the year
ended December 31, 2019, filed with the Securities and Exchange
Commission (SEC) on March 2, 2020, as supplemented by its Quarterly
Report on Form 10-Q filed with the SEC on August 10, 2020 and
subsequent filings with the SEC. Given these risks, uncertainties
and other factors, you should not place undue reliance on these
forward-looking statements, and the company assumes no obligation
to update these forward-looking statements, whether as a result of
any new information, future events or otherwise, except as required
by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201016005235/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations 360.668.3701 jennifer@cwcomm.org
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Apr 2023 to Apr 2024